Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

TheNewsWire January 17, 2023

Algernon Pharmaceuticals  (CSE:AGN) subsidiary doses first subject in Phase 1 DMT clinical stroke study

Brieanna McCutcheon  January 17, 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

GlobeNewswire January 17, 2023

Algernon Pharmaceuticals (CSE:AGN) appoints Dr. Peter Dicpinigaitis to its Chronic Cough Advisory Board

John Ballem  January 11, 2023

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

GlobeNewswire January 11, 2023

Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

TheNewsWire January 10, 2023

Algernon Pharmaceuticals (CSE:AGN) announces upcoming phase 2b chronic cough study of Ifenprodil

John Ballem  January 9, 2023

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

GlobeNewswire January 9, 2023

Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

TheNewsWire January 4, 2023

Algernon Pharmaceuticals (CSE:AGN) announces private subsidiary and SEC filing

Trevor Abes  January 3, 2023

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

GlobeNewswire January 3, 2023

Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

John Ballem  December 5, 2022

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire December 5, 2022

Algernon Pharmaceuticals (CSE:AGN) screens first subject in Phase 1 DMT Human Stroke Study

Jon Brown November 16, 2022

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

GlobeNewswire November 16, 2022

Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Newsfile November 8, 2022

Algernon Pharmaceuticals (CSE:AGN) enters into a clinical trial with Yale University for a DMT Phase 2 Depression study

Jon Brown October 24, 2022

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

GlobeNewswire October 24, 2022

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of "DMT: The Spirit Molecule" to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

GlobeNewswire October 14, 2022

Algernon Pharmaceuticals (CSE:AGN) receives C$450K cash refund from Australian research program

Azuka Onwuka September 21, 2022